Trial Profile
Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 May 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Umirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Thrombosis; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms EVERBIOII
- 28 Nov 2012 New trial record